Trials / Unknown
UnknownNCT05566535
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
Changes in Quality of Life (QoL) and Symptoms in Patients With Polycythemia Vera (PV) Receiving Ruxolitinib (Ruxo) in a Routine Clinical Practice
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 32 (estimated)
- Sponsor
- Multinational Center for Quality of Life Research, Russia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter observational prospective cohort study is to examine changes in QoL and symptoms in patients with polycythemia vera (PV) during treatment with ruxolitinib (Ruxo), and to evaluate efficacy and safety of Ruxo in a real-world setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center. |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-05-01
- Completion
- 2024-08-01
- First posted
- 2022-10-04
- Last updated
- 2022-10-04
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05566535. Inclusion in this directory is not an endorsement.